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Abstract
Compulsions are repetitive, stereotyped thoughts and behaviors designed to reduce harm. Growing evidence suggests that 
the neurocognitive mechanisms mediating behavioral inhibition (motor inhibition, cognitive inflexibility) reversal learning 
and habit formation (shift from goal-directed to habitual responding) contribute toward compulsive activity in a broad range 
of disorders. In obsessive compulsive disorder, distributed network perturbation appears focused around the prefrontal 
cortex, caudate, putamen, and associated neuro-circuitry. Obsessive compulsive disorder-related attentional set-shifting 
deficits correlated with reduced resting state functional connectivity between the dorsal caudate and the ventrolateral 
prefrontal cortex on neuroimaging. In contrast, experimental provocation of obsessive compulsive disorder symptoms 
reduced neural activation in brain regions implicated in goal-directed behavioral control (ventromedial prefrontal cortex, 
caudate) with concordant increased activation in regions implicated in habit learning (presupplementary motor area, 
putamen). The ventromedial prefrontal cortex plays a multifaceted role, integrating affective evaluative processes, flexible 
behavior, and fear learning. Findings from a neuroimaging study of Pavlovian fear reversal, in which obsessive compulsive 
disorder patients failed to flexibly update fear responses despite normal initial fear conditioning, suggest there is an absence 
of ventromedial prefrontal cortex safety signaling in obsessive compulsive disorder, which potentially undermines explicit 
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contingency knowledge and may help to explain the link between cognitive inflexibility, fear, and anxiety processing in 
compulsive disorders such as obsessive compulsive disorder.
Keywords: cognitive domains, neural circuitry, and treatment
Introduction
Compulsions are stereotyped behaviors, performed according 
to rigid rules and designed to reduce or avoid unpleasant con-
sequences (Chamberlain et al., 2009). The newly created DSM-5 
Obsessive Compulsive and Related Disorders (OCRDs) (APA 2013) 
are defined by the presence of compulsions. However, compul-
sive behaviors are observed in many other psychiatric disorders, 
particularly those involving deficient impulse control. For exam-
ple, much of the behavior associated with disorders of eating, 
substance addiction, and “behavioral addiction,” such as patho-
logical gambling or problematic internet usage (Ioannidis et al., 
2016), is theorized to shift over the course of time from reward-
driven impulsive (rapid, reckless) to compulsive activity (Everitt 
and Robbins, 2005; Robbins et al., 2012). These disorders share a 
profound experience of “lack of control,” thought to derive from 
the dysfunctional inhibition of thoughts and behaviors naturally 
prone to excess, for example, grooming, eating, purging, gam-
bling, and checking. As poorly understood lifespan disorders, 
they are difficult to treat and responsible for considerable psy-
chiatric (depression, suicide) and somatic morbidity and cost to 
the individual and society as a whole (Hollander et al., 2016).
Regrettably, the development of new treatments in psychia-
try is slowing, related, at least in part, to difficulties translating 
positive results from experiments using nonhuman illness mod-
els to the clinical setting. These difficulties align with growing 
concern about the scientific utility of the existing diagnostic sys-
tems (ICD-10, World Health Organisation 1992, DSM-5, APA 2013) 
that tend to define psychiatric disorders according to symptoms 
and syndromes and give less prominence to neuropsychological 
substrates. It is thought likely that the considerable biological 
heterogeneity that exists within the current taxonomy is ham-
pering identification of the underpinning mechanisms that may 
serve as new therapeutic targets. In response, the EU Roadmap 
for Mental Health Research in Europe (Haro et al., 2014) and the 
US National Institute of Mental Health, Research Domain Criteria 
(https://www.nimh.nih.gov/research-priorities/rdoc; Insel et  al., 
2010) have called for new ways of classifying psychopathology to 
better support treatment development based on dimensions of 
observable behavior with established biological validity, irrespec-
tive of diagnosis. Identifying the pathophysiological mechanisms 
underpinning compulsivity as a trans-diagnostic, neuropsycho-
logical domain would therefore be expected to advance the search 
for new treatment targets and support innovation in developing 
evidence-based treatments (Fineberg et al 2013a).
Many different compulsive disorders are found clustered 
within the same individual (comorbidity) or within the families 
of affected individuals, implying that vulnerability to these dis-
orders is mediated via shared pathophysiological mechanisms 
(Fineberg et  al., 2014). The investigation of endophenotypes 
(intermediate phenotypes) that lie closer than do the expressed 
behaviors (phenotypes) to the genetic and environmental ori-
gins of compulsive disorders (Gottesman and Gould, 2003; 
Chamberlain and Menzies, 2009), such as changes in cognitive 
performance, or structural and functional brain imaging abnor-
malities, is expected to provide a clearer understanding of the 
biological processes underpinning these disorders.
Based on emerging data from the neurosciences, this nar-
rative review, which was first delivered as a plenary lecture 
at the 2016 Annual Congress of the International College of 
Neuropsychopharmacology (Fineberg et  al., 2016), appraises 
the results of a decade of research by the authors dedicated to 
exploring the neuropsychological underpinnings of the OCRDs, 
as examples of compulsive disorders, from the perspective of 
diagnosis, evidence-based treatments, candidate neuro-psycho-
logical endophenotypes, and associated neural circuitry. The 
research builds upon previous and ongoing research by other 
groups and, as it has progressed, has generated testable mod-
els of compulsivity as a biologically relevant trans-diagnostic 
domain that could be expected to advance diagnostic classifi-
cation and identify new avenues for treatment, including novel 
psychological, pharmacological, and somatic treatment targets 
for these disabling and intransigent disorders.
The Obsessive-Compulsive and Related Disorders
The DSM-5 OCRD cluster, comprising obsessive–compulsive dis-
order (OCD), body dysmorphic disorder (BDD), hoarding disor-
der, hair-pulling disorder, and skin-picking disorder, represents 
some of the most costly, functionally disabling, and treatment-
resistant brain disorders. By gathering together diagnoses previ-
ously listed in the DSM-IV under Anxiety Disorders, Somatoform 
Disorders, and Impulse-Control Disorders Not Elsewhere 
Classified, this new classification aims to advance the scien-
tific study of the disorders as well as to improve their clinical 
recognition and management. The disorders commonly occur 
together and yet are surprisingly poorly recognized, as individu-
als are often not forthcoming about their symptoms (e.g., due 
to a sense of shame, or lack of knowledge that these problems 
constitute recognized mental disorders). As a result, there is 
usually a considerable time-lag, in the case of OCD, amounting 
to approximately 15 years, before the correct diagnosis is made 
and the correct treatments initiated. The duration of untreated 
illness represents one of the principal factors determining clini-
cal and health outcomes (Dell’Osso et al., 2013), emphasizing the 
importance of early detection, especially for child and adoles-
cent onset OCD (Fineberg et  al., 2013a). It is to be hoped that 
by introducing this new classification, clinicians would be more 
likely to enquire about and detect the other disorders. It is fully 
expected that the forthcoming ICD revision will adopt a simi-
lar approach and may even include additional new diagnoses 
among the OCRD grouping, such as olfactory reference syn-
drome (Marras et al., 2016).
OCRDs are generally thought to be highly heritable (hoarding 
disorder, Iervolino et  al., 2009; OCD, Nestadt et  al., 2010; BDD, 
Monzani et  al., 2012) lifespan disorders (reviewed in Steketee, 
2011; APA 2013), though episodic forms of OCD, hair pulling, and 
skin picking are seen. They are characterized by the irresistible 
urge to perform distressing and time-consuming compulsive 
acts. Of these disorders, OCD has been subject to most study 
and is arguably the most well understood. OCD affects approxi-
mately 3% of the general population, though only a fraction 
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of affected individuals present for treatment. Of considerable 
interest, subthreshold OCD is found to be extremely common 
and such cases share a similar age of onset and symptom tra-
jectory as OCD, suggesting a natural continuum of compulsive 
behavior exists affecting as many as 20% of the general popula-
tion (Fineberg et al., 2013b).
Patients with OCD show difficulty in flexibly shifting atten-
tional focus away from distressing intrusive, perseverative 
thoughts (obsessions) and behaviors (compulsions) (Fineberg 
et  al., 2010, 2014). Washing, checking, ordering, and arranging 
compulsions are extremely common. Whereas traditional learn-
ing-based psychological models of OCD posit harm avoidance as 
the major reinforcer of compulsive behaviors, some symptoms 
of OCD, especially those concerned with ordering and arranging 
to achieve symmetry, appear to reflect a need to make the envir-
onment “feel right.” Growing evidence suggests these symptoms 
represent a separate OCD subgroup, in which compulsions are 
driven by the urge to avoid an unpleasant “not just right feel-
ing.” The “not just right feeling” has been found to be associated 
with an earlier age of OCD onset and the presence of sensory 
processing difficulties (Hellriegel et  al., 2016), implicating the 
involvement of neuro-developmental mechanisms akin to aut-
ism spectrum disorder (ASD) in its etiology.
Hoarding disorder is a separate, poorly understood, and 
highly treatment refractory OCRD that involves the compulsive 
acquisition of new items and difficulty discarding owned items. 
These hoarding behaviors can also be viewed as an expres-
sion of the need to make the environment “feel right.” Typical 
responses when asking individuals what they would think/feel 
if we threw out a “treasured item,” which may be an old sweet 
paper, bus ticket, etc. are “it feels like I am missing part of me, it 
does not feel right” (Frost and Steketee, 2010). Hoarding compul-
sions are also commonly found in patients with OCD as well as 
those with neurodevelopmental disorders such as ASD. In young 
people with OCD, hoarding is associated with prominent execu-
tive function deficits (Park et al., 2016). Hair-pulling disorder and 
skin-picking disorder, on the other hand, are defined by more 
obviously disinhibited behavior, in the form of repetitive, body-
focused grooming habits that can be considered as either pre-
dominantly impulsive or compulsive, depending on the nature 
of the symptoms expressed (Chamberlain et al., 2007).
Other phenotypic signs of an altered neurodevelopmental 
trajectory are also commonly observed in patients with OCRDs, 
such as traits or symptoms of tic disorder, ASD, and attention 
deficit hyperactivity disorder. These comorbid traits and diag-
noses appear to cluster in the same patient or within their fam-
ily members, hinting that shared, heritable neuro-behavioral 
mechanisms contribute to the expression of many compulsive 
disorders (de Vries et al., 2016; Wikramanayake et al., 2017). 
Cases of tic-related OCD tend to have a male predominance 
(similar to ASD), an earlier age of onset, and a higher proportion 
of OCD symptoms related to symmetry, “not just-right experi-
ences,” and forbidden thoughts compared with non-tic-related 
OCD (Prado et al., 2008). Additionally, tic-related OCD shows a 
more favorable response to adjunctive treatment with dopa-
mine antagonist drugs (Bloch et al., 2006). In response to the 
emerging evidence, the DSM-5 has highlighted the presence of 
tic as the first neuro-behavioral specifier of a clinically relevant 
OCD subtype. Studies in patients with Tourette’s syndrome indi-
cate a complex genetic relationship exists between tic disorder, 
OCD, and attention deficit hyperactivity disorder. One such 
recent study (Darrow et al., 2016) identified two independent, 
heritable, symptom-based factors (one involving the urge to 
attain symmetry, the other involving behavioral disinhibition) 
as possible trans-diagnostic phenotypes of compulsive behavior.
Evidence-Based Treatment of OCD and Related 
Disorders
Figure 1 summarizes the evidence-based treatment of the 
OCRDs based on a systematic review (Grant et al., 2014a). Apart 
from some studies of OCD and BDD, the pharmacotherapies 
were almost exclusively tested in small un-replicated trials, 
and the psychotherapies were not rigorously tested against a 
matched control of fair comparison. Randomized controlled 
treatment trials of adequate size and power to enable the detec-
tion of predictive outcome markers are urgently needed to drive 
forward the clinical management of these disorders on an indi-
vidualized basis (Sachdev et al., 2017).
OCD typically responds to pharmacological treatment with 
serotonin reuptake inhibitors (SRIs; clomipramine and selective 
SRIs, SSRIs) according to a dose-response relationship (higher 
doses needed for better clinical response) or to SSRIs combined 
with antipsychotic agents, and to cognitive behavior ther-
apy (CBT) involving exposure and response prevention (ERP) 
(Fineberg et al., 2015). Antipsychotics represent first-line treat-
ment for Tourette’s syndrome and adjunctive antipsychotic may 
be preferentially effective in OCD with comorbid tics (Bloch et al., 
2006). BDD has been studied less intensively than OCD but also 
shows a similar treatment response (Veale et al., 2014; Rashid et 
al., 2015; Phillips et al., 2016), though it remains less clear as to 
whether higher SSRI dosages and adjunctive antipsychotic are 
of value (reviewed in Reghunandanan et al., 2015c). The com-
pulsions associated with ASD also respond to SSRI, though the 
increased risk of SSRI-induced adverse effects in the autistic 
population, such as behavioral activation and agitation, warrant 
care in dosage titration and subject selection (Kolevzon et al., 
2006). Hoarding behavior has been mainly studied in the con-
text of comorbid OCD and may respond to SSRI or venlafaxine 
(Saxena and Sumner, 2014), but as yet no effective pharmaco-
logical treatment has been established for primary hoarding dis-
order. CBT, even when delivered intensively over long periods, 
has so far been found to produce only limited improvement in 
hoarding behavior (Uhm et al., 2016). In hair-pulling disorder the 
data supporting the efficacy of SSRI and clomipramine are also 
not strong. Unlike OCD, but similar to impulse control disorders, 
SSRIs appeared to have a rapid onset of effect which was not 
sustained over time (Rothbart et al., 2013). Habit reversal ther-
apy, rather than ERP, has emerged as the psychological therapy 
of choice (McGuire et al., 2014). Other data from single rand-
omized controlled trials in hair-pulling disorder suggest that 
olanzapine (an antipsychotic agent) (Van Ameringen et al., 2010) 
and n-acetyl cysteine (an amino acid compound) (Grant et al., 
2009) could be effective. Naltrexone, an opiate antagonist, pro-
duced substantial benefits in a small open-label study of chil-
dren with hair pulling disorder (De Sousa, 2008), but the drug 
was not effective in a double-blind placebo-controlled study. 
However, those in this study with a family history of addiction 
showed a greater (but not statistically significant) decrease in 
the urge to hair-pull (Grant et al., 2014b). Skin picking disorder 
has been barely studied to date, but as with hair-pulling disorder, 
shows some response to SSRI and n-acetyl cysteine (reviewed in 
Reghunandanan et al., 2015c).
Approximately 40% of OCD patients fail to respond to stand-
ard forms of therapy (Fineberg et al., 2015). Of great interest, a 
wide range of pharmacological compounds have been tested in 
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treatment-resistant OCD and some have been found to be effect-
ive in small-sized trials, implicating a multiplicity of potential 
treatment targets and mechanisms (see Figure 2)
Thus, notwithstanding the limitations of the study data, 
some compulsive disorders (e.g., OCD, BDD) exhibit a strik-
ingly similar treatment response to SRIs, suggesting that the 
underpinning neural mechanisms may overlap significantly, 
and possibly also with those relating to anxiety and affec-
tive disorders. In contrast, hair pulling and skin picking dis-
orders, which are also characterized by prominent impulse 
control and addictive symptomatology, respond better to treat-
ment with drugs acting on dopamine, glutamate, opioid, and 
noradrenergic systems, that is, potentially more like impulse-
control disorders or even behavioral addictions (e.g. Grant et 
al., 2014b), whereas those with SRI-resistant OCD respond to 
similar agents in combination with SSRI, and OCD with promi-
nent motor symptoms (tics, habits) may respond preferentially 
to adjunctive dopamine antagonists, known to modulate the 
cortico-striatal motor circuitry involved in Tourette’s syndrome 
and animal models of excessive habit behavior (Fineberg et al., 
2014; Furlong et al., 2014).
The pharmacological treatment response may be of par-
ticular value for parsing psychiatric disorders and defining 
the boundaries of diagnostic groups, as it depends on under-
pinning biological mechanisms. As the treatment trial data for 
the OCRDs accrues, it is possible that for some disorders more 
convincing similarities will be found with disorders classified 
elsewhere in the DSM, such as the behavioral addictions (e.g., 
pathological gambling), impulse control disorders (e.g., inter-
mittent explosive disorder), or even neurodevelopmental disor-
ders (e.g. ASD), challenging their classification within the OCRDs 
grouping. Alternatively, by taking a dimensional (impulsive-
compulsive-habit) approach to the psychopharmacology of the 
OCRDs, the emerging evidence may instead be interpreted to 
support the inclusion of some of these other disorders into an 
expanded OCRDs grouping (Sachdev et al., 2017).
Neuropsychological Endophenotypes
Psychiatric symptoms and cognitive deficits can be conceptual-
ized as disordered structure, connectivity, and function in large-
scale neural networks. A series of evolutionarily well-conserved, 
parallel, cortico-striato-thalamo-cortical (CSTC) circuits are 
believed to underpin the expression of compulsive behaviors 
(Alexander et al., 1986; Cummings et al., 1993; Groenewegen and 
Uylings 2000). These circuits include direct (positive feedback) 
and indirect (negative feedback) pathways, projecting from spe-
cific cortical areas to the corresponding subregions of the stri-
atum and thalamus with recurrent projections to the cortex. 
They are involved in diverse computational activities, includ-
ing reward processing, action selection, habit formation, and 
motor control (Arnsten et  al., 2011; Robbins et  al., 2012). They 
play an important role in recognizing behaviorally significant 
stimuli (and in error detection) and in regulating goal-directed 
responses (Lovinger, 2010) and may therefore be particularly 
important for OCRDs. The anatomical overlap and functional 
Disorder Rx Psychotherapy Other
OCD SSRI
Clomipramine
Adjuncveanpsychoc
(haloperidol, risperidone,
queapine, olanzapine,
aripiprazole)
CBT with ERP
CBT+family therapy
ACT
Cingulotomy
Capsulotomy
Deep brain
smulaon
rTMS
BDD SSRI
Clomipramine
CBT with ERP
Hoarding Disorder SSRI (in comorbid OCD)
venlafaxine
CBT for hoarding
Hair-pulling Disorder Clomipramine
N-Acetyl Cysteine
Habit reversal therapy
Habit reversal therapy
ACT
Dialeccal BT
Stress Reducon
Skin picking Disorder SSRI
N-Acetyl Cysteine ACT-enhanced BT
Olanzapine
Figure 1. Evidence-based treatments for OCRDS. Adapted from Grant J, Chamberlain S, Odlaug B, Clinical Guide to OCRDs, Oxford, 2014a. Treatments with robust evi-
dence of efficacy derived from randomized controlled trials of fair comparison are highlighted in bold black type. ACT, acceptance and commitment therapy; BDD, body 
dysmorphic disorder; BT, behavior therapy; CBT, cognitive behavior therapy; ERP, exposure and response prevention; OCD, obsessive compulsive disorder; rTMS, repeti-
tive transcranial magnetic stimulation; Rx, Medication; SSRI, selective serotonin reuptake inhibitor.
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interplay between these circuits may explain why compulsive 
behavior occurs in so many psychiatric syndromes.
Historical Perspectives
Early indications that the compulsive behaviors seen in OCD and 
other compulsive disorders may be mediated by CSTC circuits 
(reviewed in Reghunandanan et al., 2015a) included research 
showing an association between postencephalitis Parkinsonian, 
obsessive-compulsive symptoms and striatal lesions (Cheyette 
and Cummings, 1995). OCD symptoms were also found to occur 
in a range of other neurological disorders involving striatal 
pathology, including Tourette’s syndrome, Sydenham’s chorea, 
Huntington’s disorder, and Parkinson’s disorder (Pitman et al., 
1987; Rapoport, 1989; Stein et al., 1994). OCD patients have sub-
sequently been found to demonstrate abnormalities in a broad 
series of measures used in neuropsychiatric (e.g., neurological 
soft signs, olfactory identification, evoked potentials, intra-corti-
cal inhibition) and neuropsychological (e.g., executive function) 
research (Stein et al., 1994; Purcell et al., 1998a). These abnor-
malities have consistently implicated CSTC dysfunction and 
impaired control of the inhibition of thoughts and behaviors 
(reviewed in Morein-Zamir et al., 2010). Some evidence has sug-
gested that they are relatively specific to disorders character-
ized by compulsive behaviors (Purcell et al., 1998b; Phillips et 
al., 2010).
Advances in brain imaging have provided persuasive neuro-
anatomical data for OCD (Rauch and Baxter, 1998; Graybiel and 
Rauch, 2000; Whiteside et al., 2004; Mataix-Cols and van den 
Heuvel, 2006; Menzies et al., 2007; Milad and Rauch, 2012) as 
well as Tourette’s syndrome (Groenewegen et al., 2003), tricho-
tillomania (Chamberlain et al., 2009), impulse control disorders 
in Parkinson’s disease (van den Heuvel et al., 2010), and addict-
ive disorders (Everitt and Robbins, 2005). Functional imaging in 
OCD has demonstrated increased activity in CSTC circuits con-
necting the orbitofrontal cortex, cingulate cortex, and striatum, 
both at rest and especially during exposure to feared stimuli 
(reviewed in Reghunandanan et al., 2015a). Somewhat different 
circuits may be involved in mediating different OCD symptom 
clusters such as hoarding (Saxena et al., 2004; Mataix-Cols 
et al., 2005). The use of sophisticated cognitive and affective 
paradigms has generated new heuristics regarding the role 
of these circuits (Fitzgerald et al., 2004; Remijnse et al., 2006); 
for example, during implicit learning, OCD subjects failed to 
show an expected increase in striatal activity and instead acti-
vated temporal cortex regions (Rauch et al., 2001). The obser-
vation that some behavioral challenges, such as exposure to 
OCD cues, induce over-activation of the orbitofrontal cortex 
on functional imaging and others induce underactivation (e.g. 
Chamberlain et al., 2008) may be explained by functional seg-
regation within the orbitofrontal cortex.
Pediatric imaging research has also supported the involve-
ment of CTSC circuits in OCD (reviewed in Reghunandanan 
et al., 2015a) and potentially offers the promise of being 
able to determine the evolution of brain abnormalities over 
time (Rosenberg and Keshavan, 1998, Rosenberg et al., 2011). 
Abnormal structure or function in other brain regions such 
as the temporal lobe structures involved in memory and fear 
processing (Hugo et al., 1999; Zungu-Dirwayi, 1999, Szeszko et 
al., 1999) and the supra marginal gyrus and the parietal lobe 
involved in the initiation and flexible control of instrumental 
behavior (Chamberlain et al., 2008; Meunier et al., 2012) have 
less commonly been found in OCD. However, recent meta- 
and mega-analyses of structural imaging data collected from 
research sites worldwide found distinct patterns of subcorti-
cal abnormalities in pediatric and adult OCD patients. The 
hippocampus as well as the pallidum seemed to be of impor-
tance in adult OCD, whereas the thalamus was involved in 
pediatric OCD (Boedhoe et al., 2017).
Both successful SRI pharmacotherapy and behavioral ther-
apy have been shown in OCD to normalize activity in CSTC 
circuits (Baxter et al., 1992). Baseline structure or activity may 
differentially predict response to pharmacotherapy and psy-
chotherapy (Brody et al., 1998; Hoexter et al., 2013) suggesting 
that different treatment modalities exert their clinical effects 
via different neuro-mechanisms (Reghunandanan et al., 2015a). 
Neurosurgical interruption of CSTC circuits may also reduce 
OCD symptoms as well as decrease striatal volume (Rauch, 2000). 
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TH
ER
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Y
Compound Study Outcome
D-amphetamine
(single dose)
Insel et al., 1983 D-amphetamine > placebo
Joffe et al., 1991 D-amphetamine > placebo
Methylphenidate = placebo
Ketamine
(IV; single dose)
Rodriguez et al., 2013 Ketamine > placebo 
Bloch et al., 2012 (open-label) No responders at 3 days
Mirtazapine Koran et al., 2005a
(double-blinded disconnuaon)
Mirtazapine > placebo
AU
GM
EN
TA
TI
O
N
Memanne Ghaleiha et al., 2013 Memanne > placebo
Haghighi et al., 2013 Memanne > placebo
Lamotrigine Bruno et al., 2012 Lamotrigine > placebo
Khalkhali et al., 2016 Lamotrigine > placebo
N-acetyl cysteine Afshar et al., 2012 N-acetyl cysteine > placebo
Sarris et al., 2015 N-acetyl cysteine = placebo
Paydary et al., 2016 N-acetyl cysteine > placebo
Costa et al, 2017 N-acetyl cysteine = placebo
Topiramate Berlin et al., 2010 Topiramate > placebo 
(compulsions only)
Mowla et al., 2010 Topiramate > placebo
Afshar et al., 2014 Topiramate = placebo
Morphine
(once weekly)
Koran et al., 2005b Morphine > placebo
Figure 2. SSRI-Resistant OCD: Small sized randomized controlled trials showing efficacy vs. placebo.
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Magnetic resonance spectroscopy has demonstrated altera-
tions in glutamate metabolites in CSTC circuits (Rosenberg et 
al., 2004; Whiteside et al., 2006; Yucel et al., 2007), in some cases 
normalizing after successful treatment with an SSRI (Rosenberg 
et al., 2000). Evidence from the relatively few positron emission 
tomography (PET) ligand studies so far performed in OCD have 
identified abnormal binding of the serotonin transporter in 
cortical and subcortical areas (Reimold et al., 2007; Matsumoto 
et al., 2010; Hesse et al., 2011) and of the striatal postsynaptic 
dopamine D2 receptor (Moresco et al., 2007; Perani et al., 2008; 
Denys et al., 2013), which normalized after treatment with SSRI 
(Moresco et al., 2007).
Techniques combining gene variants and brain imaging 
have been used to enhance the imaging findings. Several gene 
variants have been found to be associated with structural 
and functional alteration in CSTC circuits relevant to OCRDs 
(reviewed in Reghunandanan et al., 2015a). For example, in 
patients with OCD, genetic variation in the serotonin trans-
porter was demonstrated to be associated with reduced orbito-
frontal cortex volume as measured by magnetic resonance 
imaging (MRI) (Atmaca et al., 2011; Hesse, 2011) and the avail-
ability of the serotonin transporter in the putamen, nucleus 
accumbens, and hypothalamus as measured by PET (Hesse et 
al., 2011).
Thus, in OCRDs, distributed network perturbation appears 
focused around the prefrontal cortex, caudate, putamen, and 
associated neurocircuitry. In OCD, convergent evidence points 
to deficient top-down inhibitory control in the prefrontal cortex 
nodes within this circuitry, coupled with the hijacking of flex-
ible, contingency-dependent instrumental behavior in favor of 
excess habit generation mediated by dysfunction within the 
dorsal striatum (reviewed in Fineberg et al., 2014; Gillan et al., 
2016a). Abnormal activation in the dorsal striatum, especially 
the head of the caudate nucleus and the putamen, is well rep-
licated in the OCD literature (reviewed in Reghunandanan et 
al., 2015a, 2015b), implicating the cognitive fronto-striatal loop 
communicating with the dorsolateral prefrontal cortex driving 
action selection and the motor loops driving goal-directed and 
habitual responses (Gillan et al., 2014). This neuroanatomical 
model goes some way to explain the link between compulsive 
acts and harm-related thoughts and activities. Involvement of 
the putamen may be particularly relevant for the development of 
sensorimotor symptom such as tics. However, imaging research 
suggests that a wider range of CTSC circuits are involved in OCD, 
including systems responsible for reward processing more usu-
ally associated with addiction (Klanker et al., 2013).
Surgical disconnection of this circuitry via stereotactic cap-
sulotomy, cingulotomy, or limbic leucotomy has been used to 
treat severe, intractable OCD for several decades, with some 
evidence of success. A double-blind, sham-controlled trial has 
recently produced limited evidence of the efficacy and tol-
erability of ventral capsulotomy using gamma radio-surgery 
(Lopes et al., 2014, 2015; Batistuzzo et al., 2015). Promising 
results from a small number of treatment studies using inva-
sive (deep brain stimulation) or noninvasive (transcranial 
magnetic stimulation, transcranial direct current stimulation) 
methods of neuro-modulation to target either cortical (orbito-
frontal cortex, presupplementary motor area [pre-SMA]) or 
subcortical (nucleus accumbens, subthalamic nucleus) nodes 
or white matter tracts within this frontal-striatal circuitry 
(reviewed in Senço et al., 2015) indicate new treatment pos-
sibilities for refractory obsessive-compulsive disorders. There 
is experimental evidence that in patients with OCD, deep 
brain stimulation targeted to the nucleus accumbens reduced 
excessive fronto-striatal connectivity within that circuit 
(Bourne et al., 2012). The degree of such normalization corre-
lated with reduced severity of symptoms (Figee et al., 2013).
Neurocognitive Models of OCRDS
Neurocognitive changes are likely to be of great value for study-
ing the neurobiology of psychiatric disorders, as they are theo-
retically more directly linked to brain structure and function 
than are the more complex higher-level phenotypes such as 
compulsive symptoms (Fineberg et al., 2014). They are also more 
tractable to exploration across animal species (Dalley et al., 2011) 
and are invaluable for clinicians and patients, providing a richer 
understanding of the phenotype. Of the available instruments, 
computerized cognitive tests have several advantages over pen 
and paper assessment. To date, a number of tasks derived from 
the Cambridge Neuropsychological Test Automated Battery 
(CANTAB), which includes tests that are adaptable for transla-
tional work in animals and for application during brain imag-
ing, have shown considerable utility in fractionating cognitive 
processes in OCRDS and in localizing neural and neurochemical 
substrates.
Growing evidence from human and animal research using 
tests such as the CANTAB suggests that the neurocognitive 
mechanisms mediating behavioral inhibition (motor inhibition, 
cognitive inflexibility) and habit formation (shift from goal-
directed to habitual responding) variably contribute toward vul-
nerability to compulsive activity in a broad range of compulsive 
disorders (reviewed in Fineberg et al., 2014). Moreover, some of 
these deficits can be found in unaffected healthy relatives of 
OCD probands, suggesting they represent vulnerability or trait 
markers of compulsivity that also exist in nonpatient groups.
Motor Inhibition
Multiple tiers of evidence, ranging from functional magnetic 
resonance imaging (fMRI) of individuals with focal frontal 
lobe lesions to animal research, have demonstrated that the 
inhibitory control of motor acts is sub-served by a neural net-
work linking the right inferior frontal gyrus with its subcortical 
(including subthalamic) connections (Rubia et al., 2003). Motor 
inhibition can be reliably tested using the stop-signal reaction 
time (SSRT) task (Aron et al., 2005). Pharmacological manipula-
tion in rodents and humans suggests that motor response inhi-
bition, as indexed by the SSRT, falls under the neuro-modulatory 
influence of the norepinephrine system (Chamberlain et al., 
2006b, 2007a, 2013). In contrast, serotonin appears not to be cen-
trally involved in this particular measure of impulsivity (Clark 
et al., 2005a; Chamberlain et al., 2006b; reviewed in Fineberg et 
al., 2014). Paradoxically, compared with the SSRIs, there is only 
weak evidence to suggest that drugs acting to increase norepi-
nephrine in the synaptic cleft, such as the SNRIs venlafaxine 
and duloxetine (Hollander et al., 2003; Dell’Osso et al., 2008; 
Dougherty et al., 2015; Mowla et al., 2016), are beneficial in OCD.
In a series of experiments using the SSRT (Chamberlain 
et al., 2006a; Odlaug et al., 2011), evidence of significant impair-
ment in motor inhibition, compared with healthy controls, was 
found in separate groups of patients with OCD, hair-pulling, and 
gambling disorder. However, this deficit was not seen in a study 
of community respondents with obsessive compulsive person-
ality traits but without OCD (Fineberg et  al., 2015), suggesting 
that this form of inhibitory failure represents a concomitant of 
compulsive motor acts. In the case of OCD, SSRT performance 
was also highly significantly impaired in unaffected first-degree 
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relatives (Chamberlain et  al., 2007b). In a MRI study of OCD 
families that included unaffected first-degree relatives (Menzies 
et al., 2007), reduced cortical grey matter volume, coupled with 
increased basal ganglia grey matter volume, was found to cor-
relate with SSRT indices of increased motor disinhibition. This 
study produced some of the earliest evidence of a structural 
imbalance in inhibitory cortico-striatal circuitry as a neuro-
cognitive endophenotype of motor impulsivity in OCD. A more 
recent fMRI study demonstrated trait-dependent compensatory 
hyperactivity in the pre-SMA during the performance of the 
SSRT in both medication-free patients with OCD and unaffected 
siblings vs healthy controls, representing another neurocogni-
tive endophenotype of motor impulsivity, in this case possibly 
related to inefficient neural processing within the pre-SMA in 
those vulnerable to OCD (de Wit et al., 2012).
Cognitive Inflexibility
The intradimensional-extradimensional (ID-ED) shift task 
examines different components of attentional flexibility, includ-
ing reversal learning, set formation, and inhibition, as well as 
shifting attention between stimulus dimensions (ED shift). 
Studies have demonstrated that ED shift is impaired in OCD 
and additionally in the unaffected first-degree relatives of OCD 
subjects (Chamberlain et al., 2006a, 2007b; Vaghi et al., 2016), 
suggesting that this aspect of cognitive inflexibility represents 
an endophenotype for OCD-related compulsivity. Moreover, 
ED shift impairment has been identified in patients with other 
obsessive-compulsive spectrum disorders, including obsessive-
compulsive personality disorder (Fineberg et al., 2015), schizo-
phrenia with OCD (Patel et al., 2010), and BDD (Jefferies-Sewell et 
al., 2016). In a study of OCD hoarders compared with compulsive 
hoarders without OCD, significant EDS changes versus healthy 
controls were found in the OCD hoarders only, suggesting that 
the comorbid group was associated with greater cognitive 
inflexibility (Morein-Zamir et al., 2014). Interestingly, another 
study found that hair-pulling disorder was not associated with 
EDS impairment, though OCD was, suggesting that cognitive 
inflexibility is not an essential component of repetitive acts of 
grooming (Chamberlain et al., 2006a).
According to a recent fMRI analysis, compared with healthy 
controls, patients with OCD when tested in a resting state, irre-
spective of treatment status, showed reduced functional con-
nectivity in circuits linking the dorsal caudate nucleus and its 
anatomical cortical projections (Vaghi et al., 2017). In addition, 
reduced connectivity between the left dorsal caudate and the 
ventrolateral prefrontal cortex, an area of cortex known to be 
associated with EDS in healthy controls (Rogers et  al., 2000), 
was associated with reduced OCD-related EDS performance. 
The reduced functional connectivity within this circuitry may 
account for the deficits in shifting attentional focus away from 
inappropriate intrusive thoughts and rituals, resulting in the 
perseverative behavior seen in OCD and acting as a potential 
biomarker of OCD.
Perseverating on a behavior that was once rewarded, but 
is later associated with harmful consequences, may reflect a 
lack of contingency-related cognitive flexibility. Exerting flexibil-
ity in learning and unlearning behavior based on (probabilistic) 
contingencies (probabilistic reversal-learning) may be particu-
larly relevant for the development of compulsive tendencies 
(Fineberg et al., 2014). Contingency-related flexibility is depend-
ent on serotonin systems (Clarke et al., 2005b) and has been 
linked to orbito-frontal cortex (OFC) function (Rubia et al., 2003). 
Reduced activation of the OFC, lateral PFC, and parietal cortex 
was observed using task-related fMRI during reversal learning, 
not only in patients with OCD but also in their unaffected, never-
treated relatives (Rejminse et al., 2006; Chamberlain et al., 2008). 
Reversal-learning–related hypofunction, therefore, appears to 
be another candidate endophenotype for compulsivity that 
exists in people at increased genetic risk of OCD.
The identification of cognitive endophenotypes, such as 
those reflecting failures in motor inhibition and cognitive flex-
ibility, opens new perspectives for the development of bio-
markers that may be objectively quantified and used to parse 
compulsive disorders into more biologically homogeneous 
groups and that may even enable the development of personal-
ized forms of treatment tailored to the individual (Figure 3). For 
example, a small-sized, randomized, placebo-controlled trial in 
patients with skin picking disorder found that whereas lamo-
trigine was not efficacious in the group as a whole, benefit was 
seen in a subset of patients who exhibited relatively impaired 
cognitive flexibility on the EDS (Grant et al., 2010). Results such 
as these highlight the need for randomized controlled studies of 
adequate power to prospectively examine the role of cognitive 
endophenotypes as predictors of treatment response across the 
full spectrum of compulsive disorders.
Habit Learning
Compulsions are characterized by the persistence of activities 
that become disconnected from the prevailing environmental 
contingencies and lack an obvious relationship to the overall 
goal of the activity. In OCD, many patients are fully aware that 
their compulsive behaviors bear little to no relation to desirable 
outcomes, yet despite this knowledge, they continue to per-
form them. They often describe their compulsions as unwanted 
habits.
According to associative learning theories of instrumen-
tal behavior (Balleine and Dickinson, 1998; de Wit et al., 2009), 
actions are supported by at least 2 separate neural systems: a 
goal-directed system and a habitual system. When controlled 
by the goal-directed system, actions are purposeful inasmuch 
as they are flexibly performed to obtain desired goals or avoid 
undesired events. In contrast, habitual behaviors are consid-
ered lower order behaviors as they are performed as a routine 
response to specific environmental triggers and are insensi-
tive to changes in environmental contingency (i.e., whether the 
action is contextually appropriate) or the outcome value of the 
behavior (i.e., whether the goal is actually desirable). After mul-
tiple repetitions, the habit system begins to render purposeful 
behavior rigid and automatic (Adams et al., 1981, 1982), allowing 
simple acts to be conducted without effort. Exaggerated habit 
formation is consistent with the ego-dystonic stimulus-driven 
Obsessive-compulsive disorders may be differenated using tests of 
inhibitory failure, though considerable intra-class heterogeneity exists
MOTOR 
INHIBITION
COGNITIVE 
INFLEXIBILITY
OCD
SPD OCPD
Schizo
-OCD
Hoarding D
BDD
HPD
Figure 3. Motor Inhibition, Cognitive Inflexibility and OC Spectrum Dis-
orders. BDD, body-dysmorphic disorder; HPD, hair-pulling disorder; OCD, 
obsessive-compulsive disorder; OCPD, obsessive compulsive personality 
disorder; schizo-OCD, schizophrenia with OCD; SPD, skin-picking disorder.
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aspects of compulsivity. Compulsivity may thus arise at least in 
part from a shift from goal-directed action to habit, rendering 
behavior insensitive to its outcome or to the prevailing environ-
mental contingencies.
The caudate nucleus is both pivotally involved in OCD, 
as well as in the dynamic regulation of goal-directed contin-
gency learning, under the prevailing influence of the ventro-
medial prefrontal cortex (vmPFC), which tracks the current 
value of outcomes. In contrast, habitual acts involve the pos-
terior lateral putamen, where stimulus-response associations 
are stored (Balleine and O’doherty, 2010; Gillan et al., 2011). In 
a recent fMRI study of OCD patients (Banca et al., 2015), the 
experimental provocation of autobiographical compulsions in 
OCD patients was shown to reduce neural activation in brain 
regions implicated in goal-directed behavioral control (vmPFC, 
caudate nucleus) with concordant increased activation in 
regions implicated in habit learning (pre-SMA, putamen). This 
finding contrasts with previous evidence of generalized fronto-
striato-limbic hyperactivation during OCD symptom evocation 
and provocation. This is likely due to differences in task nature 
and design. The cited study used a highly ecological symptom 
provocation paradigm, which overcame some of the limitations 
of previous studies, as well as, for the first time, subject-driven 
feedback that enabled the authors to specifically address the 
link between symptom provocation and compulsive urges to 
track the motor component of OCD. By contrast, the hyperac-
tivation of caudate and medial prefrontal cortex found in pre-
vious studies could represent OCD-related changes in other 
cognitive domains such as imagery or autobiographical memory 
recollection, which are also processed in the medial prefrontal 
cortex (Lin WJ et al., 2015).
Stronger support for a shift toward habitual responding is 
derived from the following series of studies that investigated the 
extent to which patients with OCD showed a bias towards per-
forming stimulus-response habits and away from goal-directed 
activities. In the first of these studies (Gillan et al., 2011), sub-
jects were trained to respond to cues to press computer keys to 
win valuable points on a computer game. Next, some of the keys 
were devalued, that is, they were no longer linked to a valuable 
outcome and subjects were told not to press them when cued 
to do so. Yet, the OCD patients continued to habitually press in 
response to the cue, even after the keys had ceased to be linked 
to a reward.
The next study attempted to more closely model the devel-
opment of compulsions as behaviors designed to avoid harmful 
consequences (as opposed to gain appetitive outcomes), using a 
shock-avoidance task (Gillan et al., 2014). Subjects were trained 
to lever-press in response to a computer signal to avoid a mildly 
painful electric shock indicated by the signal. After excessive 
training on the task, the electric wire was obviously discon-
nected and the subjects instructed not to press in response to 
the signal. As predicted, however, patients with OCD continued 
to lever-press to the devalued stimulus that explicitly no longer 
predicted a shock and did so significantly more than a matched 
healthy control group (Gillan et al., 2014). In a subsequent study, 
this habitual shock-avoidance behavior was directly related 
to fMRI evidence of hyperactivity in both the vmPFC, during 
the initial acquisition of the goal-directed avoidance behav-
ior, and in the caudate, during the performance of the habit-
ual avoidance behaviors (Gillan et al., 2015). In addition, more 
OCD patients than controls reported experiencing a premonitory 
urge to perform the shock-avoidance habits, the intensity of 
which correlated with the performance of the habits and with 
the strength of the fMRI caudate hyperactivity. These findings 
provide compelling support for the hypothesis that compulsions 
in OCD result from a shift from goal-directed to habitual behav-
ioral control and are underpinned by changes in neural activity 
focused around the vmPFC, caudate nucleus, and the associated 
fronto-striatal neural circuitry.
Safety Signaling
The vmPFC plays a complex role in fear learning and safety-
signaling and is closely involved in integrating the evalu-
ative processing of environmental cues with flexible behavior. 
Abnormal vmPFC activation has been implicated in anxiety 
disorders (Schiller et  al., 2008; Cha et  al., 2014,) as well as in 
impaired fear retention in OCD (Milad et al., 2013). Dysfunctional 
processing within the vmPFC therefore represents a plausible 
mechanism by which explicit contingency knowledge related to 
safety and harm is undermined, leading to the failure to flex-
ibly update fear responses and the persistence of rigid, habitual 
compulsive activity. Further studies in OCD patients are there-
fore under way to clarify the neuro-psychological relationship 
between fear and anxiety processing in the vmPFC on the one 
hand and cognitive flexibility in the caudate nucleus on the 
other. A  recent neuroimaging study of Pavlovian fear reversal 
found that OCD patients failed to flexibly update fear responses, 
as measured by skin conductance changes, despite normal ini-
tial fear conditioning. This inability to update threat estimation 
was significantly correlated with vmPFC hyperactivation during 
early fear learning. The findings suggest that there is an absence 
of vmPFC safety signaling in OCD that potentially undermines 
explicit contingency knowledge and that may go some way to 
explain the link between cognitive inflexibility, fear, and anx-
iety processing in compulsive disorders such as OCD (Apergis-
Schoute et al., 2017).
Compulsive-Obsessive Disorder
In the shock avoidance studies by Gillan et al. (2014, 2015), post-
hoc explanations for continuing to respond to the devalued 
stimulus (e.g., “why did you press?”) were described as irrational 
threat beliefs by many of the OCD patients (e.g., “I thought 
I might still be shocked”). Like obsessions, these beliefs were dir-
ectly contradictory to the patients’ explicit knowledge of threat 
and their ratings of shock expectancy. Thus, in OCD subjects 
faced with aversive situations, dysfunctional activation of the 
vmPFC and dorsal striatum may disrupt normal goal-directed 
behavior, leading to the generation of harm-avoidance habits 
that readily become compulsive or urge-driven and that may 
go on to create ego-dystonic, irrational fears (obsessions) with 
the effect of perpetuating the compulsive behavior. According 
to this compulsive-obsessive disorder model, the compulsive 
behaviors of OCD play a key role in ensuring the persistence of 
the obsessions.
Consistent with this model, behavioral therapy using expos-
ure and response prevention (ERP), representing the standard 
psychological therapy for OCD (www. NICE.org.uk), requires 
patients to undergo symptom provocation via exposure to rele-
vant stimuli or situations in order to learn to resist the urge 
to perform the compulsions. ERP has been found not only to 
produce a reduction in compulsive responding, but also con-
currently causes the urge to respond and the associated obses-
sive thoughts to attenuate (Foa et al., 2005). Our data suggest 
that suppressing compulsions, for example using ERP, should 
remain a key therapeutic intervention in OCRDs and hint that 
habit reversal therapies (Morris et al., 2013) that are designed to 
break habitual associations between exposure-related cues and 
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Neurocognitive
Domain
Definition Task Neural system Neurochemistry Compulsive
disorders showing
abnormalities in
this domain
compared to
healthy controls
Motor inhibition pre-potent motor
disinhibition
stop signal reaction
time task
right inferior frontal cortex ,
SMA and subcortical
connections, including sub-
thalamic nucleus
norepinephrine OCD (and
unaffected 1st
degree relatives),
BDD,
hair-pulling disorder,
hoarding disorder,
skin picking
disorder,
gambling disorder,
binge-eating
disorder
Contingency related
cognitive inflexibility
inability to adapt
behavior after
negative feedback
reversal learning
tasks
orbitofrontal cortex and
subcortical connections
Serotonin,
Dopamine?
OCD (and
unaffected 1st
degree relatives),
pathological
gambling
Attentional inflexibility inability to switch
attention between
stimuli
extra-dimensional
attentional set-
shifting
(CANTAB)
Ventro-lateral PFC- humans.
Lateral PFC - primates
and subcortical connections
Dopamine OCD,
BDD,
OCD with
schizophrenia,
OCPD,
Anorexia nervosa,
Binge eating
disorder
Inflexible fear learning Inflexible fear
learning and
inadequate safety
signalling
Pavlovian fear
reversal
VMPFC, caudate, insula, anterior
cingulate cortex
? OCD
Habit learning Lack of sensitivity
to goals,
contingencies or
outcomes of actions
Habit formation
tasks testing
appetitive or
avoidance habit
learning under
outcome
devaluation.
Two-step
sequential
discrimination task;
model-based (goal
directed) versus
model free
(habitual) decision
making.
Fronto-striatal circuits:
Habit activity involves
connections between SMA and
posterior putamen
Goal-directed activity involves
connections between VMPFC
and caudate
Dopamine,
Serotonin?
OCD,
Binge-eating
disorder,
Methamphetamine
or cocaine abuse
Figure 4. Subdividing compulsive disorders according to neurocognitive domains: task performance, neural and neurochemical correlates. Abbreviations: CANTAB, 
Cambridge Neuropsychological Test Automated Battery; OCPD, obsessive compulsive personality disorder; PFC, prefrontal cortex; SMA, supplementary motor area; 
VMPFC, ventromedial prefrontal cortex; ?, findings not assured.
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compulsive responses and that are currently used to treat hair-
pulling disorder (Rothbart et al., 2013) may also have value in 
OCD, for example by augmenting the clinical response to ERP.
Disorders of Compulsivity: A Common Bias toward 
Learning Habits?
A number of computational modelling techniques (e.g., the 
two-step sequential discrimination task; Daw et al., 2011) have 
been developed to infer the prevailing balance between goal-
directed and habitual behavioral control by assessing a person’s 
decision-making tendencies (respectively, model-based versus 
model-free). These questionnaires and computational tasks 
have the added advantage of being readily disseminated on-line 
and therefore available to test very large numbers of subjects. 
In one of the earliest studies that applied this methodology to 
compulsivity, Voon et al. (2015a) tested a trans-diagnostic group 
of subjects with diagnoses involving both natural reward (binge 
eating disorder), artificial reward (methamphetamine/cocaine 
abuse), and OCD and compared them with healthy controls. The 
results showed a common bias across all these disorders away 
from model-based (goal-directed) learning. In addition, the habit 
formation bias was associated with lower grey matter volumes 
in the caudate and medial orbitofrontal cortex on structural MRI.
The findings suggested that dysfunction in a neurocompu-
tational mechanism favoring model-free habit learning may 
underlie the repetitive behaviors that ultimately dominate in 
diverse disorders involving compulsion. In a further study (Voon 
et al., 2015b) that compared performance on the two-step task 
under conditions of reward and loss, OCD subjects compared 
with healthy volunteers were less goal orientated (model-based) 
and more habitual (model-free) to reward outcomes with a shift 
towards greater model-based and lower habitual choices to loss 
(punishment) outcomes. These results highlight the import-
ance of motivation for learning processes in OCD and suggest 
that distinct clinical strategies based on reward valence may be 
warranted.
Most recently, Gillan et al. (2016b) applied computational 
modelling to investigate whether a dimensional approach could 
better delineate the clinical manifestations of goal-directed 
learning deficits using large-scale online assessment of psy-
chiatric symptoms and neurocognitive performance in two 
independent general population samples. Nearly 2000 people 
completed the online self-report questionnaires measuring 
decision-making preferences as well as symptoms of various 
mental health conditions. As expected, people demonstrating 
reduced goal-directed control on the two-step task (Daw et al., 
2011) also reported higher rates of compulsive symptomatology 
related to OCD and also eating disorder, impulse control dis-
order, and addiction symptoms, further demonstrating the gen-
eralizability of the deficits across multiple compulsive disorders.
By leveraging an online methodology to collect such a large 
dataset, Gillan et al. (2016b) were also able to deal with a key 
limitation of standard case-control research, the question of 
specificity. While the demonstration of a degree of generaliz-
ability of cognitive deficits across compulsive disorders that are 
similarly characterized by a loss of control over behavior, alco-
hol addiction, eating disorders, and impulsivity is of interest, 
without establishing the specificity of this deficit to this class 
of symptoms (and not depressive symptoms, for example), the 
findings are limited. By carrying out a factor analysis on their 
dataset, Gillan and colleagues identified that the self-report psy-
chopathological data could be neatly fitted into three separate 
transdiagnostic symptom dimensions: compulsive behavior 
with intrusive thought, anxious-depression, and social with-
drawal. Critically, they found that when the individual disorders 
(OCD, eating disorder, impulse control disorder, addiction) were 
replaced with the compulsive factor, the deficits in goal-directed 
control were captured even more strongly. Moreover, this asso-
ciation was highly specific when compared with the other non-
compulsive dimensions of psychopathology. These data indicate 
that deficits in goal-directed control, conferring vulnerability for 
developing rigid habits, may have a specific role in driving the 
compulsive behaviors that characterize diverse disorders such 
as OCD, eating disorder, substance abuse, and addiction.
Integrating Neuropsychological Models with 
Treatment Models
Based on these and other emerging findings, it is possible to 
draw inferences about the neuropsychological mechanisms 
underpinning the response to standard treatments in dis-
orders such as OCD (Gillan et al., 2016a). Increased stress is 
known to induce a tendency to form habits (Schwabe and Wolf, 
2009). It has therefore been suggested that SSRIs may act in 
OCD by restraining anxiety and reducing the effects of punish-
ment, thereby helping the OCD patient to switch from habitual 
towards goal-directed behavior and indirectly attenuating the 
need to perform compulsions (Morein-Zamir et al., 2013). This 
effect of SSRI could also enhance the capacity to benefit from 
CBT with ERP (Gillan et al., 2016a). The finding from a non-ran-
domized study that goal-directed learning under both reward 
and punishment conditions was enhanced in OCD patients 
receiving SSRI (Palminteri et al., 2012) provides some support 
for this hypothesis. Further support is derived from more recent 
findings in healthy volunteers that acute tryptophan deple-
tion, which reduces serotonin transmission, induced a shift 
from goal-directed to habitual responding on a slips-of-action 
test and also had a deleterious effect on model-based learning 
(Worbe et al., 2015, 2016).
However, if the mechanism of effect of SSRI in OCD 
depended on anxiety reduction, benzodiazepines and other 
anxiolytics would also be expected to show evidence of effi-
cacy, which they do not. Moreover, SSRIs are at their most 
efficacious in OCD at dosages higher than is typically recom-
mended for anxiety disorders (Fineberg et al., 2013c; Skapinakis 
et al., 2016). An alternative hypothesis, therefore, proposes 
that SSRIs exert a therapeutic effect in OCD by bolstering goal-
directed behavior through direct pharmacological actions in 
those areas of cortex implicated in safety signaling and goal-
directed control, including the vmPFC and medial orbitofrontal 
cortex (El Mansari and Blier, 2006; Gillan et al., 2015; Voon et 
al 2015a). El Mansari and Blier (2006) reviewed the effects on 
5-HT release and the adaptive changes in pre- and postsynaptic 
5-HT receptor sensitivity induced by SRI treatment in rodent 
brain structures involved in OCD, including analogues of the 
OFC. The time course of increased 5-HT release and terminal 
5-HT1D desensitization aligned with the course of the thera-
peutic response to SRI in OCD. In addition, consistent with the 
dose-dependent therapeutic effect of SRIs, a greater dose of SRI 
induced greater reuptake inhibition, which played an essential 
role in this phenomenon. The authors further hypothesized 
that the therapeutic effect of SRI-enhanced 5-HT release in the 
OFC is mediated by the activation of postsynaptic 5-HT2-like 
receptors. This cortical region is among the most consistently 
implicated in OCD (Whiteside et al., 2004) and shares overlap-
ping functional connectivity abnormalities with those seen in 
addicted individuals at rest (Meunier et al., 2012).
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Antipsychotics are used to treat stereotyped or self-injurious 
behavior in patients with ASD. It has been proposed that antip-
sychotics may also work in OCD by reducing habitual or stereo-
typed behavior patterns. The anti-OCD effect of antipsychotic 
agents, when co-administered with SSRI, has been shown to 
positively correlate with the drugs’ inherent dopamine D2 and 
D3 receptor antagonist affinities (Ducasse et al., 2014). However, 
whereas studies in rodents have identified a link between dopa-
mine in the dorsal striatum and the flexible modulation of 
learnt behavior (Lovinger et al., 2010; Furlong et al., 2014), stud-
ies of dopamine receptor agonists and antagonists in human 
models of compulsive behavior have produced ambiguous find-
ings (reviewed in Gillan et al., 2016a).
ERP for OCD involves repeated exposure to the fear-inducing 
stimuli that would ordinarily trigger a compulsive response, and 
resistance to the urge to perform the compulsion, so that the 
urge eventually dissipates. However, ERP usually involves weeks 
of practice, few people manage to drop all their compulsions, 
and about one-half of those with the condition are not helped 
at all (Reghunandanan et al., 2015b). The finding that, in OCD, 
patients may fail to flexibly update threat perception through 
faulty vmPFC safety signaling (Apergis-Schoute et al., 2017) may 
explain some of the difficulties that many experience in extin-
guishing OCD-related fears and offers exciting new treatment 
heuristics. The failure to recognize when a feared situation has 
become safe may explain why people with OCD find ERP so dif-
ficult and the treatment takes so long to work. Clinicians may 
therefore find these results helpful in their discussions with 
their patients, who could be persuaded of the importance of 
sticking with the therapy rather than giving up prematurely. 
This may even explain why co-administration of SSRI with ERP 
is found to be helpful. In addition, the new findings indicate the 
need to explore new methods of strengthening attention to safe 
situations during ERP to enhance fear-extinction, for example, 
through the use of psychopharmacological, cognitive, or neuro-
modulation strategies.
Another way in which the efficacy of ERP for OCD can be 
explained is via the systematic breaking of habitual (stimulus-
response) associations between exposure-related cues and 
compulsive responses, achieved through repeated response-pre-
vention exercises (Gillan et al., 2016). Brain-imaging measures 
of hyperactivity in the caudate nucleus of OCD patients were 
found to correlate both with goal-directed deficits and subjective 
urges to respond habitually (Gillan et al., 2014). In other studies, 
caudate abnormalities were found to be remediated when OCD 
patients respond to ERP (Baxter et al., 1992; Whiteside et al., 2012). 
These results suggest ERP may exert a direct effect on caudate 
hyperactivity. Abstinence in addiction, which results in a reduc-
tion in craving, may also work by breaking stimulus-response 
associations between cues and drug-taking behavior. However, 
both ERP and abstinence are experienced as aversive and drop-
out rates are high, reflecting the need to develop more clinic-
ally acceptable ways to deliver this form of treatment. Moreover, 
as the habitual behaviors are strengthened with repetition 
(Tricomi et al., 2009), OCD and addictions become even more dif-
ficult to treat over time, emphasizing the importance of detec-
tion and intervention at the earliest stage (Fineberg et al., 2013a; 
Gillan et al., 2016a).
Conclusions
The data presented serve to highlight the potential of a dimen-
sional, biologically grounded approach to psychiatry research. 
They suggest that vulnerability to compulsive activity can be 
predicted by a spectrum of neuropsychological mechanisms, 
including, inter alia, impaired motor inhibition, cognitive inflex-
ibility (attentional set-shift, reversal learning), and an imbal-
ance in goal-directed vs habit learning. In OCD, abnormal safety 
signaling may undermine accurate safety learning, resulting in 
inflexible threat beliefs, with important implications for expo-
sure-based therapies that rely on robust safety memories and 
future treatment development (Apergis-Schoute et al., 2017).
Avoidance habits, acting via disrupted goal-directed learn-
ing, represent a plausible model of chronic OCD-related com-
pulsivity. Furthermore, emerging evidence implicates disrupted 
goal-directed learning in an extended group of DSM disorders 
characterized by compulsive behaviors and intrusive thoughts, 
and maps with specificity onto a trans-diagnostic compulsive 
symptom-dimension. Distributed network perturbation asso-
ciated with these cognitive changes, affecting the prefrontal 
cortex (vmPFC, lateral PFC), the dorsal striatum (caudate), and 
the associated neuro-circuitry modulating emotional, cognitive, 
and motor control, has been identified in OCD. Networked stud-
ies investigating multiple disorders under the same conditions, 
head-to-head, are needed to determine the extent to which 
these changes overlap with or differentiate other disorders 
of compulsive behavior. Empirical evidence suggests that the 
psychopathology of OCRDs becomes more habitual over time. 
Mega-analysis in OCD suggests that illness-related structural 
brain changes differ in pediatric and adult cases. Longitudinal 
studies are now needed to explore the effect of duration of 
untreated disorder on the mediating neurobiology. These find-
ings would have the potential to inform (1) the development 
of biomarkers to enable the detection of compulsive disorder 
at the earliest opportunity, crucially, in children, adolescents, 
and young adults, before it becomes entrenched, as well as (2) 
the development of new treatments with novel mechanisms 
of action designed to strengthen goal-directed behavior and 
top-down cognitive strategies for controlling urges with better 
efficacy and tolerability. Agreement on a standardized set of 
validated clinical measures of compulsivity that could be used 
trans-diagnostically would represent a rational next step.
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